171 related articles for article (PubMed ID: 18945993)
1. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.
Hutchison CA; Harding S; Hewins P; Mead GP; Townsend J; Bradwell AR; Cockwell P
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1684-90. PubMed ID: 18945993
[TBL] [Abstract][Full Text] [Related]
2. Differences in kappa to lambda (kappa:lambda) ratios of serum and urinary free light chains.
Abe M; Goto T; Kosaka M; Wolfenbarger D; Weiss DT; Solomon A
Clin Exp Immunol; 1998 Feb; 111(2):457-62. PubMed ID: 9486419
[TBL] [Abstract][Full Text] [Related]
3. Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains.
Farnsworth CW; Roemmich B; Spears GM; Murray DL; Dispenzieri A; Willrich MAV
Clin Chem Lab Med; 2024 Apr; 62(5):929-938. PubMed ID: 38044587
[TBL] [Abstract][Full Text] [Related]
4. The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease.
Assi LK; McIntyre N; Fraser S; Harris S; Hutchison CA; McIntyre CW; Cockwell P; Taal MW
PLoS One; 2015; 10(7):e0129980. PubMed ID: 26132658
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the Gut Microbiome in Chronic Kidney Disease Patients and Its Association With Serum Free Immunoglobulin Light Chains.
Liu F; Xu X; Chao L; Chen K; Shao A; Sun D; Hong Y; Hu R; Jiang P; Zhang N; Xiao Y; Yan F; Feng N
Front Immunol; 2021; 12():609700. PubMed ID: 33868230
[TBL] [Abstract][Full Text] [Related]
6. A new challenge for urinary free light chains: assessment of the upper reference limit in healthy subjects.
Natali P; Debbia D; Cucinelli MR; Nasillo V; Riva G; Cigliana G; Carnazzo V; Trenti T; Marino M; Basile U
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(18):8915-8923. PubMed ID: 37782200
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker?
Caruso C; Ciasca G; Baglivo I; Di Santo R; Gasbarrini A; Firinu D; Bagnasco D; Passalacqua G; Schiappoli M; Caminati M; Canonica GW; Heffler E; Crimi C; Intravaia R; Basile V; Marino M; Colantuono S; Del Giacco S
Allergy; 2024 Feb; ():. PubMed ID: 38425088
[TBL] [Abstract][Full Text] [Related]
8. Effects of aerobic and resistance exercise for 9 months on serum free light chains in type 2 diabetes.
Kim Y; Campbell JP; Johannsen NM; Church TS; Cho E; Heaney J; Spielmann G
Front Physiol; 2024; 15():1328470. PubMed ID: 38725572
[No Abstract] [Full Text] [Related]
9. Evaluation of urinary free light chains as a marker of severity of HIV disease and its correlation with CD4 count: A Pilot Study.
Melkunte Shanthaiah D; Chitkara A; Murthy S; Srivastava D
AIDS Res Hum Retroviruses; 2024 Jun; ():. PubMed ID: 38842183
[TBL] [Abstract][Full Text] [Related]
10. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
11. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
12. Serum free light chain assessment in monoclonal gammopathy and kidney disease.
Hutchison CA; Basnayake K; Cockwell P
Nat Rev Nephrol; 2009 Nov; 5(11):621-8. PubMed ID: 19786994
[TBL] [Abstract][Full Text] [Related]
13. Validation of serum free light chain reference ranges in primary care.
Galvani L; Flanagan J; Sargazi M; Neithercut WD
Ann Clin Biochem; 2016 May; 53(Pt 3):399-404. PubMed ID: 26566665
[TBL] [Abstract][Full Text] [Related]
14. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease.
Hutchison CA; Burmeister A; Harding SJ; Basnayake K; Church H; Jesky MD; White K; Green CE; Stringer SJ; Bassett P; Ferro CJ; Cockwell P
Mayo Clin Proc; 2014 May; 89(5):615-22. PubMed ID: 24797643
[TBL] [Abstract][Full Text] [Related]
15. N Latex FLC serum free light-chain assays in patients with renal impairment.
Jacobs JF; Hoedemakers RM; Teunissen E; Te Velthuis H
Clin Chem Lab Med; 2014 Jun; 52(6):853-9. PubMed ID: 24406282
[TBL] [Abstract][Full Text] [Related]
16. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
[TBL] [Abstract][Full Text] [Related]
17. Screening panels for detection of monoclonal gammopathies.
Katzmann JA; Kyle RA; Benson J; Larson DR; Snyder MR; Lust JA; Rajkumar SV; Dispenzieri A
Clin Chem; 2009 Aug; 55(8):1517-22. PubMed ID: 19520758
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics and prognosis in patients with monoclonal gammopathy and renal damage in central China: a multicenter retrospective cohort study.
He H; Wang Z; Xu J; Liu Y; Shao Y; Hou Y; Gu J; Hu R; Xing G
Sci Rep; 2024 Apr; 14(1):7667. PubMed ID: 38561447
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a diagnostic nomogram model for predicting monoclonal gammopathy of renal significance.
Dong Y; Yan G; Zhang Y; Zhou Y; Zhu L; Shang J
Sci Rep; 2024 Jan; 14(1):990. PubMed ID: 38200026
[TBL] [Abstract][Full Text] [Related]
20. Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy.
Treger RS; Mathias PC; Cowan AJ; Green D; Hutchinson K; Bryan A; Chaudhary A; Fink SL; Wener MH; Morishima C
Am J Clin Pathol; 2024 Mar; 161(3):216-231. PubMed ID: 37936261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
